These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 18541831

  • 1. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH.
    Arch Intern Med; 2008 Jun 09; 168(11):1219-24. PubMed ID: 18541831
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May 09; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 3. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin MR.
    Pharmacoepidemiol Drug Saf; 2009 Nov 09; 18(11):1053-63. PubMed ID: 19637402
    [Abstract] [Full Text] [Related]

  • 4. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 27; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 6. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Nov 27; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 7. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec 27; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 8. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
    Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A.
    Arch Intern Med; 2005 Jan 24; 165(2):189-92. PubMed ID: 15668365
    [Abstract] [Full Text] [Related]

  • 9. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct 24; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 10. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.
    Winkelmayer WC, Waikar SS, Mogun H, Solomon DH.
    Am J Med; 2008 Dec 24; 121(12):1092-8. PubMed ID: 19028206
    [Abstract] [Full Text] [Related]

  • 11. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
    Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A.
    Aliment Pharmacol Ther; 2007 Apr 15; 25(8):913-24. PubMed ID: 17402995
    [Abstract] [Full Text] [Related]

  • 12. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 15; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 13. Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community.
    Mangoni AA, Woodman RJ, Gilbert AL, Knights KM.
    Pharmacoepidemiol Drug Saf; 2010 May 15; 19(5):490-8. PubMed ID: 20437458
    [Abstract] [Full Text] [Related]

  • 14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 15. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May 15; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 15; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 17. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
    Arthritis Res Ther; 2005 Apr 15; 7(2):R333-42. PubMed ID: 15743481
    [Abstract] [Full Text] [Related]

  • 18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 19. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
    Cheetham TC, Levy G, Niu F, Bixler F.
    Ann Pharmacother; 2009 Nov 04; 43(11):1765-73. PubMed ID: 19809010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.